Novonesis stock holds steady as share buyback program continues

Published on 09/18/2026 at 21:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novonesis stock closed at DKK 435.90 on Nasdaq Copenhagen on September 8, 2026, as the company continued a B share buyback program referenced against the September 11, 2026 closing price. The stock later traded around DKK 426.80, with technical data pointing to a neutral signal on September 17, 2026.

Industrieanlage mit Fermentationstanks eines daenischen Biotech-Unternehmens — Fotorealistische Ansicht einer Biotech-Anlage von Novonesis (Novozymes), ISIN DK0060336014, mit modernen Fermentationstanks in Bagsvaerd, Illustration mit AI erstellt.

Novonesis stock (ISIN DK0060336014) is trading in a relatively tight range on Nasdaq Copenhagen, with the B shares last recorded at a closing price of DKK 435.90 on September 8, 2026, while a company share buyback program references the closing share price on September 11, 2026 as a benchmark for its first tranche.

Share buyback sets a key reference level

According to Via Ritzau on September 18, 2026, Novonesis has structured a first tranche of its B share buyback program based on the closing share price on September 11, 2026, with that tranche corresponding to around 1.3 million B shares.

For investors, this buyback benchmark underlines how management is using the market level in mid September 2026 as a yardstick for capital returns, with the number of shares in the first tranche offering a concrete indication of the program’s scale.

Recent price levels and technical context

Per recent data from MarketScreener, Novonesis B shares closed at DKK 435.90 on Nasdaq Copenhagen on September 8, 2026, with the session showing no percent change versus the prior day, and a reported volume of 397,728 shares.

The same price table shows that on September 4, 2026 the stock closed at DKK 436.60, down 3.11% on the day, illustrating how the shares have moved from above the DKK 450 mark on September 3, 2026 to the mid DKK 430s by September 8, 2026.

In a separate technical overview, Investnow Finance lists Novonesis (Novozymes A/S) B with ISIN DK0060336014 and a neutral signal, alongside a current price indication of DKK 426.80 and an associated reference level of DKK 442.17 on September 17, 2026, highlighting that the stock was trading below this comparative value.

Stock performance and investor perspective

The movement from DKK 450.60 on September 3, 2026 to DKK 435.90 on September 8, 2026 represents a decline of around 3.3% over these sessions, with the intraday trading and closing levels suggesting some consolidation after earlier strength.

For retail investors, the combination of a neutral technical signal around DKK 426.80 in mid September 2026 and the buyback benchmark based on the September 11, 2026 closing price suggests that Novonesis management is comfortable committing capital at the current valuation, even as the stock trades below the higher reference level of DKK 442.17.

Novonesis stock price and market data

As of the last available closing snapshot, Novonesis B shares traded at DKK 435.90 on Nasdaq Copenhagen on September 8, 2026, with a daily change of 0.00% and a volume of 397,728 shares.